Cart
sales@molnova.com
Azilsartan medoxomil monopotassium
CAS No. 863031-24-7
Azilsartan medoxomil monopotassium( TAK-491 )
Catalog No. M16247 CAS No. 863031-24-7
An orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAzilsartan medoxomil monopotassium
-
NoteResearch use only, not for human use.
-
Brief DescriptionAn orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM.
-
DescriptionAn orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension. Hypertension Approved.
-
In Vitro——
-
In Vivo——
-
SynonymsTAK-491
-
PathwayGPCR/G Protein
-
TargetAngiotensin Receptor
-
RecptorAngiotensin Receptor
-
Research AreaCardiovascular Disease
-
IndicationHypertension
Chemical Information
-
CAS Number863031-24-7
-
Formula Weight606.6239
-
Molecular FormulaC30H23KN4O8
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NC(=O)O[N-]5)C(=O)OCC6=C(OC(=O)O6)C.[K+]
-
Chemical Name1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, potassium salt (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Norleual
Angiotensin IV analog. Highly potent HGF/c-MET inhibitor (IC50 = 3 pM). Inhibits HGF-induced MDCK cell proliferation and invasion in vitro. Also AT4 receptor antagonist; disrupts LTP stabilization. Antiangiogenic.
-
C-Type Natriuretic P...
CNP, a member of the natriuretic peptide family, was first identified in porcine brain and later found in other mammals as well as non-mammals. Processing of the CNP precursor gives rise to CNP-22 and its N-terminally elongated form, CNP-53. The CNPs share considerable sequence homology with ANP and BNP within the disulfide loop and exert similar pharmacological actions, although with different relative potencies.
-
Saralasin
Competitive non-selective angiotensin II antagonist.
